[ET Net News Agency, 12 October 2021] Hansoh Pharmaceutical Group Company Limited
(03692) said Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh
Pharmaceutical Group Company Ltd. (collectively, the licensees), each a wholly-owned
subsidiary of the company, have entered into an exclusive licence and collaboration
agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950) (OliX Pharmaceuticals).
OliX Pharmaceuticals will use its GalNAc-asiRNA platform technology to discover lead
compounds and secure development candidates for targets in cardiovascular, metabolic, and
other diseases associated with the liver. Hansoh will have the exclusive commercial rights
to these therapeutics in China (including Hong Kong, Macau and Taiwan) and OliX
Pharmaceuticals will have the rights in the rest of the world. OliX Pharmaceuticals will
receive initial upfront payment of US$6.5 million with up to US$450 million plus royalties
based on key milestones. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03692 HANSOH PHARMA
Nominal 
15.380 -0.280 (-1.788%) Others
12/10/2021 15:47
Hansoh Pharma (03692) units sign licensing agreement
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |